Hai Yi Ma

Hai Yi Ma was the founder of ScinoPharm Taiwan Ltd., founded in 1997, serving as President, Chief Executive Officer & Director from 1997 to 2014.
Dr. Ma is also the founder of Vivo Capital LLC..
Current positions include Executive Director at Taiwan Bio Industry Organization; Director at TWi Pharmaceuticals Holding, Inc.; Independent Director at Lumosa Therapeutics Co., Ltd. since 2021; Director at Formosa Pharmaceuticals, Inc. since 2017; Independent Director at BioGend Therapeutics Co., Ltd. since 2018; Independent Director at Steminent Biotherapeutics, Inc. since 2024; and Director at Obigen Pharma, Inc. since 2021.
Former positions include Chairman-Pharmaceutical Production Committee at Pharmaceutical Research & Manufacturers of America; Independent Director at Crown Bioscience, Inc.; Director at TWi Pharmaceuticals, Inc.; Director at Reber Genetics Co., Ltd.; Independent Director at Crown Bioscience International; Corporate Vice President-Pharmaceutical Technology at Syntex Corp.; and Manager-Electronic Materials Plant at Monsanto Co. Education includes a doctorate from Lehigh University, graduate studies at the University of Iowa, and undergraduate studies at National Taiwan University.